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One of the most dramatic changes in the ﬁeld of oncology is the
rapid development of oral anticancer medications (OAMs). With
the approval of drugs such as capecitabine in 1998 [1] and
imatinib in 2001 [2], oncology entered a new era and there are
currently more than 50 Food and Drug Administration–approved
OAMs with many more in the clinical trials pipeline (Table 1).
Although oral drugs may be more convenient [3–5], decrease the
need for infusion equipment, and reduce the number of out-
patient visits [6], there are challenges with adherence, persis-
tence, and costs [7–11].
Unlike intravenous (IV) chemotherapy, which is covered under
the medical beneﬁt component of insurance plans, most OAMs are
covered by prescription drug plans. A limited list of OAMs for which
there is an injectable equivalent is covered under medical beneﬁts
(e.g., capecitabine) [12], but most of the new OAMs do not have an
IV equivalent, and may be a patient’s best or only option for
treatment. This distinction is important because out-of-pocket
(OOP) costs for patients can be substantially different based on
whether medications are covered by medical beneﬁts versus
prescription drug plans. Medical beneﬁts typically require patients
to pay a co-payment (e.g., $20–$50 per dose) or coinsurance (e.g.,20% of the plan’s allowed amount) for chemotherapy given in the
outpatient setting, and include the cost of the drug and its
administration. Although a 20% coinsurance may be substantial
with high-cost chemotherapy, most of the Medicare beneﬁciaries
have supplementary insurance [13] that offsets their OOP costs for
services covered under medical beneﬁts. However, pharmacy cover-
age often has tiered co-payment structures and other requirements
that may increase cost sharing for more expensivemedications [14].
Cost sharing for cancer patients can lead to the inability to afford
basic needs [15,16], nonadherence [15,16], and even bankruptcy [15].
Discrepancies in coverage have led advocates to call for parity
between oral and IV chemotherapy in hopes of reducing OOP costs
for patients requiring OAMs and improving adherence.The Path to Drug Parity in Oncology
The term “parity” for health beneﬁts was ﬁrst coined in reference
to equal coverage for mental health and substance abuse serv-
ices. Historically, traditional beneﬁt designs covered mental
health and substance abuse services with a higher cost sharing
(e.g., 50% coinsurance) and “inside” limits (e.g., 20 annual visits)
than did medical and surgical beneﬁts. The path to mental health
parity has been a long, dynamic process that began with theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – List of oral anticancer medications that are FDA approved (as of May 2015).
Generic Brand National drug code Date of initial
FDA approval
Indication Medicare
Part B or D
Is a generic
available?
Abiaterone
acetate
Zytiga 57894-150 4/28/11 Metastatic castrate-resistant prostate cancer either before
or after chemotherapy
D No
Anagrelide Agrylin 54092-063 3/1997 Thrombocytopenia associated with myeloproliferative
disorders
D Yes
Anastrozole Arimidex 54868-5000 (PTC) 9/25/05 First-line treatment of locally advanced or metastatic
breast cancer (hormone receptor–positive or unknown)
in postmenopausal women, advanced breast cancer
following tamoxifen, adjuvant treatment of receptor-
positive breast cancer in postmenopausal women
D Yes
0310-0201 (AZ)
Afatinib Gilotrif 0597-0137 (BIP) 7/12/13 First-line treatment of NSCLC with EGFR mutation D No
0597-0138 (BIP)
0597-0141 (BIP)
Axitnib Inlyta 0069-0145 (Pﬁzer) 1/27/12 Treatment of advanced renal cell carcinoma after failure of
one previous therapy
D No
0069-0151 (Pﬁzer)
Bexarotene Targretin 62856-602 12/29/99 Cutaneous manifestations of cutaneous T-cell lymphoma
in patients who are refractory to one previous systemic
therapy
D No
Biclutamide Casodex 54868-4503 (PTC) 10/4/95 Metastatic prostate cancer in combination with an LHRH
agonist
D Yes
0310-0705 (AZ)
Bosutinib
monohydrate
Bosulif 0069-0135 (Pﬁzer) 9/4/12 Treatment of chronic, accelerated, or blast-phase
Philadelphia chromosome-positive CML
D No
0069-0136 (Pﬁzer)
Busulfan Myleran 0173-0713 (GSK) 6/26/54 Palliative treatment of CML B No
76388-713 (Asp global)
Cabozantinib Cometriq 42388-013 (Exelixis) 11/29/12 Treatment of progressive metastatic medullary thyroid
cancer
D No
42388-014 (Exelixis)
Capecitabine Xeloda 0004-1100 (Gen) 4/30/98 Metastatic colorectal cancer, adjuvant therapy of Dukes’ C
colon cancer, metastatic breast cancer
B Yes
0004-1101 (Gen)
53808-0411 (st of FL)
54868-4143 (PTC)
54868-5260 (PTC)
Ceritinib Zykadia 0078-0640-70 (Novartis) 4/29/14 Treatment of patients with ALK-positive, metastatic
NSCLC with disease progression on or who are
intolerant to crizotinib
D No
Chlorambucil Leukeran 76388-635 (asp global) 3/18/57 Management of CLL, Hodgkin lymphoma, non-Hodgkin
lymphomas
D No
0173-0635 (GSK)
Crizotinib Xalkori 0069-8140 (Pﬁzer) 8/26/11 Metastatic NSCLC whose tumors are ALK positive D No
0069-8141 (Pﬁzer)
Dabrafenib Taﬁnlar 0173-0846 (GSK) 5/29/13 For the treatment of patients with unresectable or
metastatic melanoma with BRAF V600E mutation as
detected by an FDA-approved test
D No
0173-0847 (GSK)
Dasatinib Sprycel 0003-0524 (E.R.) 6/28/06 Treatment of CML in chronic, accelerated,
or blast-phase resistant or intolerant to previous
therapy (including imatinib), treatment of newly
diagnosed Philadelphia chromosome–positive CML in
D No
0003-0527 (E.R.)
0003-0528 (E.R.)
0003-0852 (E.R.)
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Table 1 – continued
Generic Brand National drug code Date of initial
FDA approval
Indication Medicare
Part B or D
Is a generic
available?
chronic phase, Phþ ALL resistant or intolerant to
previous therapy
0003-0855 (E.R.)
0003-0857 (E.R.)
54868-5759 (PTC)
Enzalutamide Xtandi 0469-0125 (Astellas) 8/31/12 Treatment of metastatic castration-resistant prostate
cancer who previously received docetaxel
D No
Erlotinib Tarceva 50242-062 (Gen) 11/18/04 Treatment of locally advanced or metastatic NSCLC
refractor to at least one previous chemotherapy regimen
(as monotherapy); maintenance treatment of locally
advanced or metastatic NCSLC that has not progressed
after four to six cycles of ﬁrst-line platinum- based
chemotherapy, locally advanced, unresectable, or
metastatic pancreatic cancer (ﬁrst line in combination
with gemcitabine)
D No
50242-063 (Gen)
50242-064 (Gen)
54868-5290 (PTC)
54868-5447 (PTC)
54868-5474 (PTC)
Estramustine Emcyt 0013-0132 (Pharm Up) 12/24/81 Palliative treatment of progressive or metastatic prostate
cancer
D No
Etoposide Vepesid 003783266 12/30/86 Treatment of small cell lung cancer B Yes
Everolimus Aﬁnitor 0078-0566 (Novartis) 3/30/09 Treatment of advanced RCC, after sunitinib or sorafenib
failure; treatment of subependymal giant cell
astrocytoma associated with tuberous sclerosis; in
patients who are not candidates for curative surgical
resection of advanced, metastatic, or unresectable PNET
B No
0078-0567 (Novartis)
0078-0594 (Novartis)
0078-0620 (Novartis)
0078-0626 (Novartis)
0078-0627 (Novartis)
0078-0628 (Novartis)
Exemestane Aromasin 54868-5261 (PTC) 1/21/99 Treatment of advanced breast cancer in postmenopausal
women whose disease has progressed following
tamoxifen therapy; adjuvant treatment of
postmenopausal estrogen receptor–positive early breast
cancer following 2–3 y of tamoxifen
D Yes
0009-7663 (Pharm up)
Fludarabine Oforta 0024-5820 (SA) 4/18/91 Treatment of progressive or refractory B-cell chronic
lymphocytic leukemia
B Yes
Flutamide Eulexin 49884-753 (Par) NA Treatment of metastatic prostate cancer in combination
with an LHRH agonist
D Yes
60429-272 (GSMS)
0172-4960 (IVAX)
0591-2466 (Watson)
Geﬁtinib Iressa 0310-0482 (AZ) 7/13/15 First-line treatment of patients with metastatic NSCLC
whose tumors have epidermal growth factor receptor
exon 19 deletions or exon 21 substitution mutations as
detected by an FDA-approved test
D No
Hydroxyurea Hydrea 0003-0830 (E.R.) 12/7/67 Treatment of melanoma, refractory CML, recurrent,
metastatic, or inoperable ovarian cancer,
radiosensitizing agent in treatment of squamous cell
head and neck cancer (excluding lip)
D Yes
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Ibrutinib Imbruvica 57962-140 (Pharmacyclics) 11/13/13 Patients with mantle cell lymphoma who have received at
least one previous therapy. Approved for CLL in patients
who have already received one other therapy (2/2014)
D No
Idelalisib Zydelig 61958-1702-1
(GileadSciences, Inc.)
7/23/14 Treatment of patients with relapsed CLL, in combination
with rituximab, for whom rituximab alone would be
considered appropriate therapy due to other
comorbidities
D No
61958-1701-1
Imatinib Gleevec 66828-0030 (Novartis) 4/18/03 Treatment of GIST, kit positive, including unresectable
and/or metastatic malignant and adjuvant following
complete resection; Phþ CML in chronic phase, blast
phase, or accelerated phase after failure of IFN; Phþ ALL,
Dermatoﬁbrosarcoma protuberans, hypereosinophilic
syndromes, and/or chronic eosinophilic leukemia; MDS/
MPD associated with platelet-derived growth factor
receptor gene rearrangements
D No
0078-0401 (Novartis)
0078-0438 (Novartis)
54868-5289 (PTC)
54868-5427 (PTC)
Lapatinib Tykerb 0173-0752 (GSK) 3/13/07 Treatment of Her2 overexpressing advanced or metastatic
breast cancer (in combination with capecitabine) in
patients who received previous therapy (with
anthracylin, taxane, and trastuzumab) and HER2
overexpressing hormone receptor–positive metastatic
breast cancer in postmenopausal women (in
combination with letrozole)
D No
Lenalidomide Revlimid 59572-402 (Celgene) 12/27/05 Treatment of low- or intermediate-1-risk MDS in patients
with del 5q with transfusion-dependent anemia;
treatment of multiple myeloma (in combination with
dexamethasone) in patients who have received at least
one previous therapy, mantle cell lymphoma whose
disease has progressed after two previous therapies, one
of which included bortezomib
D No
59572-405 (Celgene)
59572-410 (Celgene)
59572-415 (Celgene)
59572-425 (Celgene)
Letrozole Femara 54868-4151 (PTC) 7/25/97 Adjuvant treatment of hormone receptor–positive early
breast cancer in postmenopausal women; extended
adjuvant treatment of early breast cancer after 5 y of
tamoxifen; advanced breast cancer
D Yes
0078-0249 (Novartis)
Lenvatinib Lenvima 62856-710-30 (Eisai Inc) 2/13/15 Treatment of patients with locally recurrent or metastatic,
progressive, radioactive iodine-refractory differentiated
thyroid cancer
D No
62856-720-30
Lomustine CeeNu 0015-3030 (E.R.) 8/4/76 Treatment of primary and metastatic brain tumors (after
surgery or radiation); treatment of relapse or refractory
Hodgkin disease (as part of a combination)
D No
0015-3031 (E.R.)
0015-3032 (E.R.)
Melphalan Alkeran 52609-0001 (Apo) 1/17/64 Palliative treatment of multiple myeloma and
nonresectable epithelial ovarian cancer
B No
Mercaptopurine Purinethol 57844-522 (Gate) 9/11/53 Maintenance treatment component of ALL Yes
Methotrexate
sodium
NA 75840-111 (GenPak) 8/1/94 Treatment of trophoblastic neoplasms, ALL, meningeal
leukemia, breast cancer, head and neck cancer,
cutaneous T-cell lymphoma, lung cancer (squamous
and small cell), advanced NHL, osteosarcoma
B Yes
0054-4550 (Roxane)
Nilotinib Tasigna 0078-0526 (Novartis) 10/29/07 Treatment of newly diagnosed PHþ CML in chronic phase;
treatment of chronic and accelerated-phase Phþ CML
D No
0078-0592 (Novartis)
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Table 1 – continued
Generic Brand National drug code Date of initial
FDA approval
Indication Medicare
Part B or D
Is a generic
available?
refractory or intolerant to previous therapy (including
imatinib)
Olaparib Lynparza 0310-0657-58 (AZ) 12/19/14 Treatment as monotherapy in patients with germline
mutations in BRCA in advanced ovarian cancer treated
with three or more previous lines of chemotherapy
D No
Panobinostat Farydak 0078-0650-06 (Novartis) 2/23/15 In combination with bortezomib and dexamethasone for
the treatment of patients with multiple myeloma who
have received at least two previous regimens, including
bortezomib and an immunomodulatory agent
D No
0078-0651-06 (Novartis)
0078-0652-06 (Novartis)
Pazopanib Votrient 0173-0804 (GSK) 10/19/09 Treatment of advanced renal cell carcinoma, advanced
soft tissue sarcoma who have received previous therapy
D No
Procarbazine Matulane 54482-053 (Sigma) 7/22/69 Treatment of Hodgkin disease D No
Regorafenib Stivarga 50419-171 (Bayer) 9/27/12 Treatment of patients with metastatic colorectal cancer
who have previously been treated with 5FU, oxaliplatin,
and irinotecan-based chemotherapy, a VEGF inhibitor,
and if Kras WT, anti-EGFR therapy
Ruxolitinib Jakaﬁ 50881-005 (Incyte) 11/16/11 Treatment of intermediate- and high-risk myeloﬁbrosis D No
50881-010 (Incyte)
50881-015 (Incyte)
50881-020 (Incyte)
50881-025 (Incyte)
Sonidegib Odomzo 0078-0645 (Novartis) 7/24/15 Treatment of adult patients with locally advanced basal
cell carcinoma that has recurred following surgery or
radiation therapy, or those who are not candidates for
surgery or radiation therapy
D No
Sorafenib Nexavar 50419-488 (Bayer) 12/20/05 Treatment of advanced renal cell carcinoma; treatment of
unresectable hepatocellular carcinoma, treatment of
locally recurrent or metastatic differentiated thyroid
cancer refractory to radioactive iodine
D No
Sunitinib Sutent 0069-0550 (Pﬁzer) 1/26/06 Treatment of gastrointestinal stromal tumors intolerant or
progression on imatinib; treatment of advanced RCC;
treatment of advanced, metastatic, or unresectable
pancreatic neuroendocrine tumors
D No
0069-0770 (Pﬁzer)
0069-0980 (Pﬁzer)
Tamoxifen Nolvadex 54868-3004 (PTC) 12/30/77 Treatment of male or female breast cancer; adjuvant
treatment of breast cancer after primary treatment with
surgery and radiation; reduce risk of invasive breast
cancer in women with DCIS after surgery and radiation;
reduce the incidence of breast cancer in women at high
risk
D Yes
54868-4287 (PTC)
63629-4413 (Bryant)
63739-269 (McKesson)
0093-0782 (Teva)
0093-0784 (Teva)
0378-0144 (Mylan)
0378-0274 (Mylan)
0591-2232 (Watson)
0591-2233 (Watson)
0591-2472 (Watson)
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Temozolamide Temodar 54868-4142 (PTC) 8/11/99 Treatment of newly diagnosed glioblastoma multiforme
(initially in combination with radiotherapy, then as
maintenance); treatment of refractory anaplastic
astrocytoma
B No
54868-5348 (PTC)
54868-5350 (PTC)
54868-5354 (PTC)
54868-5980 (PTC)
0085-1366 (Merck)
0085-1417 (Merck)
0085-1425 (Merck)
0085-1430 (Merck)
0085-1519 (Merck)
Thalidomide Thalomid 59572-205 (Celgene) 7/16/88 Treatment of newly diagnosed multiple myeloma D No
59572-210 (Celgene)
59572-215 (Celgene)
59572-220 (Celgene)
Thioguanine Tabloid 0173-0880 (GSK) 1/18/66 Treatment of AML D No
Topotecan Hycamtin 0007-4205 (GSK) Treatment of metastatic ovarian cancer, relapsed or
refractory small cell lung cancer, recurrent or resistant
stage IVB cervical cancer (in combination with cisplatin)
B No
0007-4207 (GSK)
Trametinib Mekinist 0173-0848 (GSK) 5/29/13 Treatment of unresectable or metastatic melanoma with
BRAF mutation
D No
0173-0849 (GSK)
0173-0858 (GSK)
Tretinoin Atralin 005550808 7/26/07 Induction of remission of patients with APL D Yes
Vandetanib Caprelsa 0310-7810 (AZ) 4/6/11 Treatment of progressive medullary thyroid cancer D No
0310-7820 (AZ)
0310-7830 (AZ)
0310-7840 (AZ)
Vemurafenib Zelboraf 50242-090 (Gen) 8/17/11 Treatment of unresectable or metastatic melanoma with
BRAF mutation
D No
Vismodegib Erivedge 50242-140 (Gen) 1/30/12 Treatment of metastatic basal cell carcinoma or locally
advanced not able to get surgery or radiation
D No
Vorinostat Zolinza 0006-0568 (Merck) 10/6/06 Treatment of progressive, persistent, or recurrent CTCL D No
ALK, anaplastic lymphoma kinase; Apo, Apo-Pharma USA, Inc.; Ari, ARIAD Pharmaceuticals, Inc; asp global, Aspen Global; AZ, AstraZeneca Pharmaceuticals LP; Bayer, Bayer HealthCare
Pharmaceuticals Inc.; Bryant, Bryant Ranch Prepack; Celgene, Celgene Corporation; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTCL, cutaneous T-cell lymphoma; DCIS,
ductal carcinoma insitu; EGFR, epidermal growth factor; E.R., E.R. Squibb and Sons, LLC; FDA, Food and Drug Administration; Gate, Gate Pharmaceuticals; Gen, Genentec; GIST, gastrointestinal
stromal tumor; GSK, GlaxoSmithKline LLC; GenPak, GenPak Solutions LLC; GSMS, Golden State Medical Supply, Inc.; IVAX, IVAX Pharmaceuticals, Inc.; LHRH, luteinizing hormone-releasing
hormone; McKesson, McKesson Packaging Services Business Unit of McKesson Corporation; MDS/MPD, myelodysplastic syndrome/myeloproliferative disorder; Merck, Merck Sharp & Dohme
Corp.; Mylan, Mylan Pharmaceuticals Inc. Novartis, Novartis Pharmaceuticals Corporation; NSCLC; non–small cell lung cancer; Par, Par Pharmaceuticals; PD-RX, PD-Rx Pharmaceuticals, Inc.;
Pﬁzer, Pﬁzer Laboratories Div Pﬁzer Inc.; Pharm up, Pharmacia and Upjohn Company; PNET, pancreatic neuroendocrine tumor; PTC, Physicians Total Care, Inc.; RCC, renal cell carcinoma;
Roxane, Roxane Laboratories, Inc; SA, Sanoﬁ-aventis U.S. LLC; Sigma, Sigma-Tau Pharmaceuticals, Inc.; st of FL, state of Florida; Teva, Teva Pharmaceuticals USA Inc.; VEGF, vascular endothelial
growth factor; Watson, Watson Laboratories, Inc.; WT, Wilms tumor.
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Table 2 – Current state laws for caps on out-of-
pocket costs and drug parity for cancer agents (as of
August 2015).
State Name of bill (capped
amount if applicable)
Date of
enactment
Arizona HB 2078 1/1/16
California* AB 219 ($200 cap, allows for
annual increase, not more
than CPI)
1/1/15
Colorado HB 1202 1/1/11
Connecticut SB 50/PA 10-63 1/1/11
Delaware HB 265 1/1/13
District of
Colombia
Bill No. 18-278/Act No. 18-
225/D.C. Law 18-98
12/17/09
Florida* HB 1159 (Ch. 2013-153 Section
641.313) ($50 cap)
1/1/14
Georgia* HB 943 ($200 cap) 7/1/15
Hawaii HB 1964 amended an existing
law
1/1/10
Illinois HB 1825/PA 97-0198 1/1/12
Indiana SB 437 1/1/10
Iowa Iowa Code 514C.24 1/1/09
Kansas HB 2160 4/1/10
Kentucky* HB126 ($100 cap) 1/1/15
Louisiana* HB 693/Act No. 410 ($100 cap) 1/1/13
Maine LD 627 1/1/15
Maryland SB 179/HB 243 10/1/12
Massachusetts S 2363 5/1/13
Minnesota SF 1761 5/14/10
Missouri* SB 668 ($75 cap, allows for
increase based on CPI
1/1/15
Nebraska LB 882 10/1/12
Nevada* SB 266 ($100 cap) 1/1/15
New Jersey SB 1834 7/16/12
New Mexico SB 385 6/17/11
New York SB 450/HB 1273 S. 3988/A.
6233
1/1/12
North Dakota HB 1072 4/14/15
Ohio* SB 99 ($100 cap) 1/1/15
Oklahoma† SB765 ($100 cap) 11/1/13
Oregon SB 8 1/1/08
Rhode Island SB 428/H5354 1/1/14
Texas HB 438 9/1/11
Utah* SB189 ($300 cap) 10/1/13
Vermont HB 444/VT No. 61 4/1/10
Virginia SB 450/HB 1273 7/1/12
Washington HB1517 1/1/12
Wisconsin* SB 300 ($100 cap) 1/1/15
Wyoming SB 62 7/1/15
AB, Assembly Bill; CPI, consumer price index; HB, House Bill; No.,
number; SB, Senate Bill.
* These state laws do not require parity; instead they cap
coinsurance/co-payments for a 30-d supply of an oral
anticancer medication.
† Oklahoma’s law mandates both oral parity and a cap.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 – 9 894enactment of state parity laws in the 1990s. State laws, however,
had little impact partly because health plans that fell under the
Employee Retirement Income Security Act of 1974 (ERISA) were
exempt from the requirements of state laws [17]. In 2008, the
Mental Health Parity and Addiction Equity Act (MHPAEA) required
self-insured plans covered under ERISA to offer mental health and
substance abuse coverage with no more restriction than did other
medical and surgical procedures covered under the plan. This law
applied only to policies with existing mental health beneﬁts, and
did not mandate plans to begin offering mental health coverage
[18]. The Patient Protection and Affordable Care Act (ACA) of 2010
mandated nongrandfathered health plans to include essential
health beneﬁts, which included mental health and substance use
disorder services [19,20]. Essential health beneﬁts, however, do not
apply to self-insured ERISA plans and thus gaps continue to exist.
The path to drug parity in oncology is following a similar trend,
and many states have responded to the increasing number of
OAMs and rising costs by introducing drug parity legislation. Drug
parity laws require group and individual private plans to cover
OAMs with the percent cost sharing that is “no less favorable than
that provided for intravenous/injected chemotherapy.” Some of
the early states to enact laws have loopholes and allow insurers to
increase cost sharing under medical plans for IV agents to match
cost sharing for oral drugs (Oregon, District of Columbia, Indiana,
Iowa, Kansas, Vermont, Washington, and Virginia), but the more
recently enacted laws do not permit this. Some states do not offer
full parity, but rather a maximum allowed cost sharing for a 30-
day supply of an OAM (see Table 2). This maximum amount varies
from $50 (Florida) to $300 (Utah), and some states allow this
maximum amount to increase annually based on inﬂation (Cal-
ifornia and Missouri). Currently, 36 states plus the District of
Columbia have passed a law that addresses either parity or caps
OOP expenses for OAMs (Fig. 1 and Table 2) [21–49]. Major cancer
organizations, including the Patients Equal Access Coalition, the
International Myeloma Foundation, the Leukemia and Lymphoma
Society, the American Cancer Society, the American Society of
Hematology, and the American Society of Clinical Oncology have
advocacy efforts supporting drug parity by formally endorsing
both state and federal laws.
At the federal level, US Representative Brian Higgins (D-NY)
proposed a bill to expand oral drug parity to all employer-
sponsored plans covered by ERISA (H.R. 2366) in May 2009, but
it was not enacted [50]. It was reintroduced in August 2011 and
August 2013 as the Cancer Drug Coverage Parity Act of 2013 (H.R.
1801) [51,52]. Similar legislation, the Cancer Treatment Parity Act
(S. 1879), was introduced to the Senate in December 2013 by
Senators Al Franken (D-MN) and Mark Kirk (R-IL) [53] but died at
the end of the year before consideration by the House or the
Senate. It is unclear why these bills have not progressed through
the legislative process, but it is likely that the issue has not
reached a high enough national priority to be addressed. In June
2015, bipartisan federal legislation, the Cancer Drug Coverage
Parity Act of 2015, was once again reintroduced to the 114th
Congress in both the Senate (SB1566) and the House (HR2739).
State Drug Parity Laws Have Limited Scope and Important
Barriers
There are two basic types of private employer-based health
insurance plans: an “insured health plan” and a “self-insured”
(also referred to as “self-funded”) plan. An insured plan requires
the employers to purchase health care coverage for their employ-
ees from an insurance company and pay a premium each year for
that coverage. Self-insured plans require the employer to pay
directly into a plan that pays the beneﬁt claims instead of using
an insurance company, and a third party administers these
plans. Self-insured plans are regulated at the federal level byERISA, which sets minimum standards for many employee
beneﬁts including health coverage.
A major limitation of a state law is their narrow scope because
they affect only fully insured private insurance plans; self-
insured plans and public insurance (i.e., Medicare, Medicaid) are
not required to comply. A 2013 Kaiser Family Foundation report
found that 48% of Americans are covered by employee-based
private insurance, 6% other private, 16% Medicaid, 15% Medicare
State with a drug parity 
law passed
State with no law  
Fig. 1 – States with laws for drug parity laws or out-of-pocket maximum for oral anticancer medications (as of August 2015).
(Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 – 9 8 95(or have dual private and Medicare coverage), and 13% are
uninsured [54]. Of the 48% with employee-based private insur-
ance, 45% had fully insured plans and therefore would be
required to abide by a state drug parity law [54]. Therefore, even
if every state passed a drug parity law, most of the Americans
would be covered by an insurance plan that is not affected by
the law.
For patients who do stand to beneﬁt from state laws, the goal
is to decrease OOP expenses, increase access to OAMs, and
reduce the ﬁnancial burden [16,55–57], but the laws need further
analysis to see whether this goal is being accomplished. A major
assumption that parity laws make is that OAMs consistently have
higher OOP cost than do IV drugs; however, recent data show that
this may not be true for targeted anticancer drugs, which account
for 63% of all chemotherapy in 2011 [58]. An analysis of prescrip-
tion drug claims of more than 70 million nonelderly individuals
with private insurance demonstrated that insurance payments
for targeted OAM more than doubled over 10 years, which was
more than that seen with targeted IV drugs. With respect to OOP
cost, however, the OOP spending for targeted OAMs was less than
half the amount for targeted IV anticancer drugs. In this scenario,
a drug parity law could potentially even increase costs for
patients by equalizing the cost sharing between oral and IV
drugs. There has also been concern that oral parity legislation
will lead to increased insurance premiums [59]. Analyses have
shown that parity may increase the premium costs by 0.0039% to
0.2% per year, which equates to an increase of 0.04¢ to $1.00 per
member per month in premiums [60–62]; however, these analy-
ses fail to account for rising drug prices and therefore may
underestimate the true premium cost increases.
Another potential limitation to the effectiveness of drug parity
laws is that health plans may respond to the laws by increasing
the use of nonprice rationing techniques such as prior author-
ization to create access barriers for patients. This issue was
anticipated in mental health parity, and the MHPEA regulations
deﬁned what was termed “nonquantitative treatment limits
(NQTLs),” which included strict standards with regard to the
management of prescription drug formulary structure, methods
for establishing fees, and prior authorizations. The NQTL regu-
lations speciﬁed that a health plan may not impose management
strategies for mental health that were more stringent than that
for medical or surgical services [63]. In the case of drug parity
laws in oncology, evaluation of nonprice rationing techniques
should be undertaken to see whether they are being used andsimilar NQTL provisions should be incorporated into existing and
future laws.
Drug Parity Laws, Rising Drug Costs, and Value
Drug parity laws attempt to address the disparity between the
coverage of IV drugs and OAMs, but they fall short of providing a
solution to the underlying problem of rising costs [64]. An area of
increasing interest and national debate is value-based insurance
design (VBID), which provides incentives for use of high-value
services and discourages low-value services with high cost shar-
ing for patients. The VBID was incorporated into Section 2713 of
the ACA [65] and requires coverage for preventative care, well-
ness visits, and treatments such as medications to control blood
pressure or diabetes at low or no cost with the goal of preventing
future expensive complications. To illustrate the concept behind
VBID, most Americans pay the same cost share for every type of
doctor within their network despite their quality, or every drug
within the tier of the formulary, despite of its clinical beneﬁts.
The VBID has at its core the concept of incentivizing patients and
physicians to choose high-value treatment options by setting the
consumer cost-sharing level on clinical beneﬁt, not acquisition
price, of the service (or drug). For example, although the cost
sharing of imatinib in chronic myelogenous leukemia should be
zero or very low, it should be kept at current tiers for indications
for which its clinical beneﬁts or level of evidence are not well
proven. Furthermore, there are many discussions on how to
deﬁnitely determine the “value” of individual cancer therapies,
regardless of the route of administration. The American Society
of Clinical Oncology Value in Cancer Care Task Force is develop-
ing an algorithm to determine the value of treatments incorpo-
rating clinical beneﬁt, toxicity, and cost [66]. These ﬁndings,
however, are not available currently, and it is unclear how this
will be adopted into clinical practice.
Existing drug parity laws are not agile enough to vary cost
sharing on the basis of effectiveness or value. The fundamental
aim of drug parity does not intersect with VBID goals and they
cannot coexist in their current form. Under VBID, chemotherapy
agents (oral or IV) with low value would have high cost sharing to
disincentivize their use. With oral parity, however, the level of
cost sharing would be required to be on par with IV chemo-
therapy and without consideration of value. The impact of
lower cost sharing due to drug parity legislation may have the
unintended consequence of making patients less sensitive to
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 – 9 896and aware of the total costs, and thus undermine the goals of
value-based care. It is also possible that pharmaceutical com-
panies will simply raise drug prices to counteract drug
parity consequences, ultimately increasing total costs [14,67]
For this reason, drug parity laws fail to address the underlying
challenge of unsustainably increasing total costs of
cancer drugs.
The ACA Introduces Progress beyond Parity
The ACA does not mandate drug parity in oncology; however, it
does contain provisions that may impact oral chemotherapy.
OOP limits
Under the ACA, all nongrandfathered health plans must comply
with an annual OOP maximum of $6,600 per individual and
$13,200 per family in 2015. Although an annual limit may be
helpful, patients with high-percentage coinsurances may not be
able to afford even the ﬁrst month’s prescription, which may lead
to abandoning the drug [68]. Another potential limitation is that
only costs associated with “covered” services count toward the
OOP maximum, so ensuring that oral chemotherapy is consid-
ered covered is essential.
Closing the donut hole
By 2020, the coverage gap in prescription drug plans will incre-
mentally decrease annually until it is reduced to 25% of the drug
cost for both brand name and generic drugs. Pharmaceutical
companies have been instrumental in phasing out the donut hole
for brand name drugs by offering a 50% manufacturer discount
beginning in 2011. The remaining coverage of the donut hole will
be through government subsidy. This offers some relief from OOP
expenses; however, with the high cost of most OAMs, 25% still
remains a substantial burden for many Americans.
Essential beneﬁts
The ACA requires all public and private health plans to offer a
comprehensive package of items and services, known as essen-
tial health beneﬁts. Essential health beneﬁts must include items
and services within at least the following 10 categories: ambula-
tory patient services, emergency services, hospitalization, mater-
nity and newborn care, mental health and substance use disorder
service, prescription drugs, rehabilitative services and devices,
laboratory services, preventative services, and pediatric services,
including oral and vision care. Although the essential beneﬁts do
require prescription drug coverage, the law makes no speciﬁc
mandate for drug parity in oncology.
ERISA amendments
The ACA included the amendment, section 2709, into section 715
(a) (1) of ERISA [69], which requires coverage for approved clinical
trials for cancer patients. There is currently no amendment
requiring drug parity for OAMs, but as discussed above, the
MHPAEA successfully amended ERISA in mental health and
serves as a potential model for oncology.
In the case of mental health parity, the ACA and the MHPAEA
successfully interacted to greatly extend the reach of the original
MHPAEA legislation. The implementation of the ACA translated
into MHPAEA parity protections being given to those gaining
coverage through the exchanges and Medicaid expansion, and
expanded requirements to existing plans in the small group and
individual market [63]. In oncology, however, the ACA and
existing drug parity laws do not interact effectively to expand
the scope of the laws or increase access to OAMs because they do
not mandate ERISA plans as did the MHPAEA in mental health.Future Policy Is Necessary to Contain Costs of OAMs
As cancer therapy rapidly evolves, changes must take place both
in the pricing and in the coverage of chemotherapy, both IV and
oral. Drug parity laws are not designed to lower the total price of
high-cost cancer drugs, so additional policy is necessary. The
pricing of new oncology drugs has been the topic of debate and
scrutiny, and in President Obama’s 2016 budget request to
Congress, he included consideration to allow Medicare to nego-
tiate prices with drug manufacturers, similar to the Department
of Veterans Affairs. Although this solution has potential to offer
lower total prices, it must be carefully balanced with the high cost
of developing new and novel cancer therapies. Reference pricing
[70], a practice in which insurers pay a ﬁxed price for all drugs of
similar clinical beneﬁt, has been introduced as a potential
strategy to stabilize the cost of oncologic treatments. This
approach appears to have promise; however, it raises concern
that comparative effectiveness data are lacking and it is uncer-
tain what factors (i.e., survival vs. toxicity vs. route of admin-
istration) would deﬁne equivalency [71]. A method of controlling
the pricing of all oncology drugs is timely introduction of generics
as well as the development of biosimilar agents [72]. A challenge
with biosimilars is determining whether they are truly inter-
changeable with the reference product.
The Centers for Medicare and Medicaid Services has pro-
posed the Oncology Care Model [73] that would continue fee-for-
service payment for ofﬁce visits, procedures, and drugs and
would add a per-beneﬁciary-per-month payment for services
provided during a designated 6-month “episode.” In addition, a
performance-based payment would be given on the basis of
savings and meeting designated quality measures. The Oncology
Care Model may be an important ﬁrst step; however, it does not
include a value-based design and it continues to cover oral
chemotherapy and IV chemotherapy under different payment
structures. Insurers must change the way they have historically
covered chemotherapy where value, rather than the route of
administration, is factored into the amount of cost sharing for
the patient. A potential model would include oral and IV
chemotherapy under the same coverage plan, similar to drug
parity laws, and cost sharing would be based on a value-based
design, although as discussed earlier, there is considerable
debate on what constitutes “value” in oncology care. Because
different practice settings and patient populations may have
different needs, exploring various payment models will be
important.Conclusions
Although the optimal plan for ﬁnancing oral chemotherapy is
unclear at this point, it is certain that the number of OAMs is
increasing, the number of cancer patients is rising, the duration
of treatment for even advanced disease is lengthening, and the
cost of oncology drugs is continuing to soar. Thus, it is imperative
that we develop wide-reaching ﬁnancial solutions to continue to
provide high-quality and affordable care for cancer patients,
regardless of the route of drug administration. Drug parity laws
alone fall short by being limited in scope and failing to address
the underlying problem of rising total cancer costs. Lowering
total cancer care costs will likely involve many policy changes
including innovation in drug pricing to include value, introduc-
tion of performance-based payment, and a shift from coverage
based on the route of administration. Ultimately, combining
principles of parity in chemotherapy coverage with innovative
pricing and payment models will help ensure access and afford-
able care for cancer patients being treated with OAMs.
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